Advertisement

Topics

[News] NICE guidance on cabozantinib for previously treated advanced renal cell carcinoma

21:30 EDT 8 Aug 2017 | The Lancet

On August 9, 2017, the National Institute for Health and Care Excellence (NICE) published technology appraisal guidance1 recommending cabozantinib, within its marketing authorisation, as an option for the treatment of advanced renal cell carcinoma in adults after VEGF-targeting therapy, only if the company provides cabozantinib with the discount agreed.

Original Article: [News] NICE guidance on cabozantinib for previously treated advanced renal cell carcinoma

NEXT ARTICLE

More From BioPortfolio on "[News] NICE guidance on cabozantinib for previously treated advanced renal cell carcinoma"

Quick Search
Advertisement
 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Renal Cell Carcinoma
Renal cell cancer (renal adenocarcinoma or hypernephroma) is the most common type of kidney cancer in adults. More than 8 in every 10 (80%) kidney cancers diagnosed in the UK are this type.  In renal cell cancer the cancerous cells start in the lini...